The AI Eye: Veritone's (NASDAQ: VERI) aiWARE Receives FedRAMP Approval and Viome Collaborating with Helomics to Study Cancer with AI
Point Roberts, WA and Vancouver, BC - March 25, 2019 (Investorideas.com Newswire) Investorideas.com, a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye watching stock news, deal tracker and advancements in artificial intelligence.
Listen to today's podcast:
The AI Eye: Veritone's (Nasdaq:VERI) aiWARE Receives FedRAMP Approval and Viome Collaborating with Helomics to Study Cancer with AI
Today's Column - The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence
AI-Based Chatbot Market to Reach $2.2 Billion by 2024
A new report from Research and Markets indicates that the AI-based chatbot market will reach $2.2 billion globally by 2024. An excerpt from the report summary reads:
Artificial Intelligence (AI) enabled chatbots are taking Customer Relationship Management (CRM) to a new level as business-to-business, business-to-consumer, and consumer-to-business communications is both automated and improved by way of push and pull of the right information at the right time. Chatbots also provide benefits to customers as both existing clients and prospects enjoy the freedom to interact on their own terms. Our research indicates that over 50% of customer queries may be managed today via AI-based chatbots.
Veritone's aiWARE Receives FedRAMP Approval and Viome Collaborating with Helomics to Study Cancer with AI
Stocks discussed: (NasdaqGM:VERI) (NasdaqCM:AIPT)
Veritone, Inc. (NasdaqGM:VERI) has received Federal Risk and Authorization Management Program (FedRAMP) Authorization for its aiWARE platform. aiWARE is a government platform which "orchestrates an expanding ecosystem of machine learning models to transform audio, video and other data sources into actionable intelligence". Ryan Steelberg, president of Veritone, said:
"Achieving a FedRAMP Authorization is a huge milestone for Veritone and validates our AI platform as a viable and secure option for federal agencies to leverage artificial intelligence to accomplish their missions more efficiently and effectively. Because our aiWARE Government platform fulfilled the rigorous security requirements to achieve a FedRAMP Authorization, individual agencies can now expedite the procurement and use of our AI offerings."
Health tech firm Viome has announced a collaboration with Precision Therapeutics Inc. (NasdaqCM:AIPT) company Helomics to study the link between the gut microbiome and ovarian cancer. The study will see Viome's proprietary microbiome analysis platform and artificial intelligence (AI) platform. Gerald Vardzel, President and CEO of Helomics Corporation, said:
"Helomics pioneered using knowledge gained from drug response and genomic profiling of the patient's living tumor to help individualize ovarian cancer therapy. The collaboration with Viome is groundbreaking, generating data from the microbiome combined with our existing data and using our respective AI platforms, to offer an innovative, holistic and personalized approach to helping oncologists choose the best treatment options for patients with ovarian cancer."
Sam Mowers, Investorideas.com
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.
Visit the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, contents creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: More disclaimer info: shttps://www.investorideas.com/About/Disclaimer.asp ,
Learn more about our podcast and article services and costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
The AI Eye - Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com
800 665 0411